

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

U-87MG Uppsala

RRID:CVCL_GP63

Type: Cell Line

Proper Citation

RRID:CVCL_GP63

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_GP63

Proper Citation: RRID:CVCL_GP63

Description: Cell line U-87MG Uppsala is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Glioblastoma

Defining Citation: [PMID:2454731](#), [PMID:4134536](#), [PMID:4313504](#), [PMID:4337530](#), [PMID:4369403](#), [PMID:27582061](#)

Comments: Caution: This is the original U-87MG cell line established in 1968 at the University of Uppsala. The cell line distributed by most cell collections (including ATCC, CLS, ECACC, etc.) is a different cell line whose origin is not yet clear (PubMed=27582061). See U-87MG ATCC (Cellosaurus=CVCL_0022) for the cell line used by most research groups.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: U-87MG Uppsala

Synonyms: U-87MG, U-87 MG, U87 MG, U-87-MG, U87-MG, U87MG, U-87, U87, 87 MG, 87MG

Cross References: Wikidata:Q28575999

ID: CVCL_GP63

Record Creation Time: 20220427T221639+0000

Ratings and Alerts

No rating or validation information has been found for U-87MG Uppsala.

No alerts have been found for U-87MG Uppsala.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Fujimoto K, et al. (2026) Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profiles. *Acta neuropathologica*, 151(1), 15.

Sui M, et al. (2026) ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair. *Molecular cancer research : MCR*, 24(1), 7.

Zhou S, et al. (2026) Vascular normalization by erianin unleashes CAR-T immunotherapy in glioblastoma. *Angiogenesis*, 29(2), 18.

Goncharov NV, et al. (2025) Therapy enhancing chromosome instability may be advantageous for IDH1 R132H/WT gliomas. *NAR cancer*, 7(1), zcaf003.

Tian H, et al. (2025) ⁶⁴Cu-Labeled Stapled Peptide-Based Radiopharmaceuticals Targeting MDM2/MDMX for Pan-p53 Tumors. *Journal of medicinal chemistry*, 68(21), 23389.

Jain S, et al. (2024) Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(15), 3287.

Daisy Precilla S, et al. (2023) Repurposing synthetic and natural derivatives induces apoptosis in an orthotopic glioma-induced xenograft model by modulating WNT/β-catenin signaling. *Fundamental & clinical pharmacology*, 37(6), 1179.

Chen C, et al. (2022) Doramectin inhibits glioblastoma cell survival via regulation of autophagy in vitro and in vivo. *International journal of oncology*, 60(3).

Giassafaki LN, et al. (2021) Towards analyzing the potential of exosomes to deliver microRNA therapeutics. *Journal of cellular physiology*, 236(2), 1529.